Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000152816 | SCV000202212 | uncertain significance | not provided | 2014-02-25 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001079208 | SCV001019571 | benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2024-10-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002516068 | SCV003691634 | uncertain significance | Inborn genetic diseases | 2022-09-29 | criteria provided, single submitter | clinical testing | The c.3281G>A (p.C1094Y) alteration is located in exon 9 (coding exon 9) of the ATRX gene. This alteration results from a G to A substitution at nucleotide position 3281, causing the cysteine (C) at amino acid position 1094 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001079208 | SCV002087308 | benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2019-10-28 | no assertion criteria provided | clinical testing |